Use of 3–[(3S,4R)–3–methyl–6–(7H–pyrrolo[2,3–d]pyrimidin–4–yl)–1,6–diazaspiro[3,4]octan-1–yl]–3–oxypropionitrile or its salts

TWI931329BActive Publication Date: 2026-07-11ROHTO PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW109126866
Authority / Receiving Office
TW · TW
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-12-27
Filing Date
2020-08-07
Publication Date
2026-07-11
Estimated Expiration
2040-08-06

Smart Images

  • Figure IMG-2_DRAW_109126866-A0304-14-0001-1
    Figure IMG-2_DRAW_109126866-A0304-14-0001-1
  • Figure IMG-2_DRAW_109126866-A0304-14-0002-2
    Figure IMG-2_DRAW_109126866-A0304-14-0002-2
  • Figure IMG-2_DRAW_109126866-A0304-14-0003-3
    Figure IMG-2_DRAW_109126866-A0304-14-0003-3
Patent Text Reader

Abstract

This invention relates to an ophthalmic composition for promoting tear secretion, which contains 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidine-4-yl)-1,6-diazaspiro[3.4]octane-1-yl]-3-oxopropanenitrile or a salt thereof.
Need to check novelty before this filing date? Find Prior Art